UK-CAB 24 – BHIVA 2007 clinical audit – microbicides – PEPSE – PrEP – Pfizer
25 January 2008
Programme
| 09.00 – 09.30 | Registration and welcome |
| 09.30 – 10.00 | UKCAB updates and conference feedback |
| 10.00 – 10.45 | BHIVA 2007 audit: treatment of naïve patients – Dr Hilary Curtis, BHIVA clinical audit co-ordinator |
| 10.45 – 11.00 | Break |
| 11.00 – 11.15 | Pfizer pre-meeting |
| 11.15 – 12.30 | Company meeting: Pfizer |
| 12.30 – 14.00 | Lunch |
| 14.00 – 14.45 | Campaigning for microbicides – Eunice Sinyemu, African and Minority Ethnic HIV Project and UK African Microbicides Working Group, Toju Cline-Cole, THT and UK African Microbicides Working Group |
| 14.45 – 15.15 | Promoting PEPSE: what is the role of HIV treatment advocates? – Elias Phiri, THT |
| 15.15 – 15.30 | Break |
| 15.30 – 16.00 | PrEP: pre-exposure prophylaxis – Gus Cairns, freelance journalist |
| 16.00 – 16.30 | AOB, next meeting etc |
Background reading
BHIVA 2007 audit
Dr Hilary Curtis will present findings from treatment of BHIVA’s 2007 audit of treatment of naïve patients.
BHIVA clinical audit report 2006-7 PDF 108 Kb
BHIVA audit 2006-7: cohort audit of patients starting ART from naïve PowerPoint 146 Kb
Patient organisations and ABPI code of practice
Background reading for the Pfizer pre-meeting – ABPI code of practice and the consultation from European Federation of Pharmaceutical Industries and Associations (EFPIA) regarding interactions with patient organisations.
Working consultatively Prescription Medicines Code of Practice Authority
Prescription Medicines Code of Practice Authority, 333 Kb
Pfizer – The drug development process
Pfizer representatives will present on the processes used in the search for new medicines.
Research and development at Pfizer Pfizer
Campaigning for microbicides
The word “microbicides” refers to a range of different products that share one common characteristic: the ability to prevent the sexual transmission of HIV and other sexually transmitted infections when applied topically. A microbicide could be produced in many forms, including gels, creams, suppositories, films, or as a sponge or ring that releases the active ingredient over time.
About microbicides Global Campaign for Microbicides
The Global Campaign for Microbicides is a broad-based, international effort to build support among policymakers, opinion leaders, and the general public for increased investment into microbicides and other user-controlled prevention methods.
Women, HIV and microbicides seminar report PDF George House Trust and UK African Microbicides Working Group, 210 Kb
Promoting PEPSE
BASSH guidelines for post-exposure prophylaxis after sexual exposure (PEPSE) to HIV includes a review of the current data to support the use of PEPSE.
UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure PDF BASSH, 180 Kb. This document includes a review of the current data to support the use of PEPSE.
PEP for sexual exposure to HIV doesn’t lead to more risky sex Aidsmap
Accessing post-exposure prophylaxis (PEP) after sexual risk: the experiences of homosexually active men in England International AIDS Society (IAS)
Pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) – where ARVs are given before possible exposure to HIV – is the subject of current research.
Will a pill a day prevent HIV? Anticipating the results of the tenofovir “PREP” trials PDF AIDS Vaccine Advocacy Coalition (AVAC), 640 Kb
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.
The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.